Get started
BioCryst Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsSeasonalsOptionsETFs

What traders are saying


Join the conversation. Discover trade ideas, share insights, and see how others read the market.
BCRX - Institutional Ownership: 95% Sales Growth: +37% (YoY) for the last quarter. The company raised its revenue forecast for Orladeyo to $590 - $600 million for 2025. ✅ OVERCOMING (over 30%). Gross Margin: For their core product Orladeyo, the margin is over 90%. Overall, for the company, as scale improves, gross profitability remains extremely high. ✅ OVERCOMING. 🏢 Institutional Ownership This is one of BCRX's strongest points right now: Institutional Ownership: ~92.5% to 97.7% (according to various sources as of end-2025). Trend: Big players like Vanguard and BlackRock hold huge positions. The fact that institutions own almost all of the outstanding shares shows that the smart money believes in the long-term potential for $1 billion in sales by 2029. 🚀 Why YES (Buy): Breakthrough: BioCryst officially reached EPS in the second half of 2025. They are no longer a cash-burning company, but one that generates it. Huge upside: The average analyst price target is $20.60, which is about a 170% increase from current levels (~$7.50). Acquisition of Astria: The purchase of Astria Therapeutics (expected to close in Q1 2026) gives them a new drug in the pipeline that could protect them from competition in the future. ⚠️ Risks (Why to be careful): Single-product dependency: Almost all revenue comes from Orladeyo. If a better alternative emerges, the risk is high. Competition: New products from giants like Takeda could slow their growth.
NASDAQ:BCRXLong
by SimeonNikolaev-invest
BCRXBioCryst Pharmaceuticals, Inc. is a U.S. biotechnology company headquartered in Durham, North Carolina, specializing in the development of oral small-molecule therapies and injectable proteins for rare and serious diseases. ORLADEYO (berotralstat) is the cornerstone of BioCryst's recent commercial success. It is an oral preventive treatment, taken once daily, for attacks of Hereditary Angioedema (HAE). It was approved by the FDA in December 2020 and has been launched in multiple global markets. The ORLADEYO market expansion continues with the recent FDA approval of oral pellets for pediatric HAE patients aged 2 to under 12 years. This approval extends the drug's availability to approximately 500 diagnosed pediatric patients, of which around 40% are currently on treatment, further driving demand and bringing the company closer to its peak sales goal of $1 billion. ORLADEYO net revenue in the third quarter of 2025 reached $159.1 million, representing an impressive 37% year-over-year growth. Thanks to this performance, BioCryst raised its ORLADEYO revenue forecast for fiscal year 2025 to a range of $590 million to $600 million. BioCryst's financial results for the third quarter of 2025 show strong momentum, with significant revenue growth from ORLADEYO and expectations of profitability for the full year, ahead of schedule. Expansion BioCryst Pharmaceuticals has signed a definitive agreement to acquire Astria Therapeutics, a biotechnology company focused on transformative therapies for patients with allergic and immunological diseases. Navenibart (STAR-0215)—a long-acting injectable preventive treatment designed for HAE attacks—is the primary asset driving the acquisition's value for BioCryst. Although Navenibart is the main driver of the acquisition, STAR-0310—a monoclonal antibody OX40 antagonist designed with the potential to be a first-choice treatment for Atopic Dermatitis (AD)—introduces significant diversification value. The transaction is expected to close in the first quarter of 2026. BioCryst maintains a research and development focus beyond HAE, centered on the development of its next-generation oral Factor D inhibitor, BCX10013. Other assets in the portfolio include BCX17725, for which an Investigational New Drug (IND) application was submitted in the U.S. for Netherton syndrome. Key Points • BioCryst has created an effective monopoly in the two preferred dosing modalities for HAE prophylaxis: daily oral (ORLADEYO) and ultra-low-frequency injectable (Navenibart). • The company has demonstrated strong financial management, securing growth capital through the monetization of peripheral assets and achieving profitability ahead of schedule. • STAR-0310 represents a high-potential differentiation asset that, if successful, could unlock significant value in a much larger market than HAE. Technical Analysis The company's stock price action supports a likely medium- and long-term upside. The presence of large volumes and the rounded shape of the accumulation reveal strong institutional investor presence.
NASDAQ:BCRXLong
by OldWave96
BCRX - Different this time? I propose that there will be no further rejection from .382 after the one we have just seen (in green rectangle) which has been used to form a support This support is something that has been lacking in all the past jumps in price, making me think that this time will be very different Another idea that supports this is the indecision shown on the Gaussian Channel indicator, price is within a relatively tight range, these ranges which often are made to be broken
NASDAQ:BCRX
by Bixley
A Great Risk Reward Opportunity!Hi everyone, Yurii Domaranskyi here. Let's take a look at the chart: 1. Price levels are working good here 2. Globally and locally uptrend 3. The level confirmed by FB 4. All-time high 5. enough room for 1 to 5.1 r/r 6. The price came from below 7. Report on FEBRUARY 23 8. A near test what is bad for short but it stoped below the level 9. No news for the last 10 days Potential risk/reward ratio = 1 to 5.1 meaning that potential risk 100$ with the possibility to make 510$ If it does make sense to you, press a thumb up! 👍
NASDAQ:BCRXShort
by trading_as_bus
$BCRX retrospective lookRetrospective look at $BCRX: 1. Gap down to lower low aligning with oversold signal on RSI (Blue Circle). 2. Continued downtrend forming Descending Triangle (Pink Dashed) following hypotenuse resistance line and flat support line. 3. Double bottom then forms (Green Box & Dotted Line and Orange Arrow) within the converging trendlines. 4. Simultaneous bullish signal on the RSI indicator (Blue Dotted Line). 5. Breakout over resistance trendline with large volume (Blue Volume Circle) 6. RR 1.2:1 take profit could have captured initial move (Long position). Easier to spot now it's happened! Hope this will add to my (and potentially others) knowledge/experience. Any comments appreciated *Not financial advice*
NASDAQ:BCRX
by Angus_Ed
16 things to know about this stock!Hi everyone, Yurii Domaranskyi here. Let's take a look at the chart: 1. Price levels are working well. 2. Globally downtrend locally uptrend. 3. The level is confirmed by many false breakouts. 4. Near test, but we see a pin bar on the last day 5. Approached with big bars 6. Approached with no rollbacks 7. There is accumulation in from of the level, but I still see this as a short because of the pin bar 8. there was not a rollback on the way up 9. closed under the level 10. level of a gap 11. there is enough room for a move 1 to 5.1 12. there is a model ascending lows *which is against short idea* 13. no news for the last 10 days 14. the price came from below 15. the stock has a good potential for a big move down 16. no report in the following 2 weeks Potential risk/reward ratio = 1 to 5.1 meaning that potential risk 100$ with the possibility to make 510$ If you find my work valuable, please, press a thumb up! 👍
NASDAQ:BCRXLong
by trading_as_bus